Eganelisib (IPI 549), a novel PI3K-y inhibitor, induced promising response rates when added to nivolumab (Opdivo) for the treatment of patients with metastatic urothelial carcinoma (mUC), according to results of a phase 2 trial.
“PD-1 inhibitors have demonstrated clinical benefit in metastatic urothelial carcinoma. However, clinical benefit remains low, particularly in PD-L1—low patients, who have [an average] overall response rate of only 16%,” study author Piotr Tomczak, of the Poznan University of Medical Sciences in Poznan, Poland, said in a presentation at the 2021 Genitourinary Cancers Symposium where the data were read out.
The MARIO-275 study (NCT03980041) included 49 patients with mUC who progressed on 1 or more platinum-based chemotherapy regimens and had no prior treatment with a checkpoint inhibitor. Study participants were stratified by baseline circulating monocytic…
